Vyvanse® (lisdexamfetamine) is a stimulant medication used for the treatment of attention deficit hyperactivity disorder (ADHD), approved for use in patients 6 years of age and older. On August 28, the generic lisdexamfetamine was approved, and pharmacies are beginning to receive this product. For Ohio Medicaid patients, brand name Vyvanse® is the preferred option as of September 2023. Generic lisdexamfetamine will not be covered without a prior authorization. When issuing a prescription for Vyvanse® for Ohio Medicaid patients, prescribers can mark the prescription with Dispense As Written 9 (DAW 9). A DAW 9 code instructs the pharmacy that the patient’s insurance requests the brand name product over a generic. Using this code should prevent a pharmacy from automatically filling a generic product. For more information on the approval, see the FDA below.
Vyvanse® Generics Now FDA Approved
Related Articles
Flovent® Brand Name Inhalers Are Being Discontinued
Read More
PFK Asthma Risk Portal: Identify and Learn About Your High-Risk Asthma Patients
Learn more about the Asthma Risk Portal and view the training manual.
Read More
Update: Nirsevimab 100 mg Syringe Shortage
Learn more about the Nirsevimab 100 mg Syringe Shortage.
Read More
Quarterly Update for Partners For Kids Pediatric-Focused Unified Preferred Drug List
Access the most recent unified preferred drug list.
Read More
Partners For Kids Coverage Tools Support Cost Savings and Decrease Prior Authorization Burden
Read how Partners For Kids pharmacy resources can help providers align therapy decisions with managed care organization’s formularies, generate cost savings and avoid prior authorizations.
Read More
Respiratory Syncytial Virus (RSV) Prevention Resource
Read More